Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & Administrative
Others
Ratios

Pasithea Therapeutics (KTTA) EPS (Weighted Average and Diluted) (2021 - 2024)

Pasithea Therapeutics (KTTA) has disclosed EPS (Weighted Average and Diluted) for 4 consecutive years, with -$2.41 as the latest value for Q4 2024.

  • Quarterly EPS (Weighted Average and Diluted) rose 46.56% to -$2.41 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$12.69 through Dec 2024, changed 0.31% year-over-year, with the annual reading at -$2.91 for FY2025, 77.07% up from the prior year.
  • EPS (Weighted Average and Diluted) hit -$2.41 in Q4 2024 for Pasithea Therapeutics, up from -$2.87 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.06 in Q4 2021 to a low of -$8.98 in Q4 2022.
  • Historically, EPS (Weighted Average and Diluted) has averaged -$2.32 across 4 years, with a median of -$2.6 in 2023.
  • Biggest YoY gain for EPS (Weighted Average and Diluted) was 49.78% in 2023; the steepest drop was 18269.45% in 2023.
  • Year by year, EPS (Weighted Average and Diluted) stood at $0.06 in 2021, then crashed by 14927.42% to -$8.98 in 2022, then skyrocketed by 49.78% to -$4.51 in 2023, then soared by 46.56% to -$2.41 in 2024.
  • Business Quant data shows EPS (Weighted Average and Diluted) for KTTA at -$2.41 in Q4 2024, -$2.87 in Q3 2024, and -$3.71 in Q2 2024.